Multi-Omics and Molecular Simulation Identify KIF11 as a Candidate Direct Target of Resveratrol in Hepatocellular Carcinoma
Journal of Hepatocellular Carcinoma · 2026-08 · Volume 13 · 1-26
DOI: 10.2147/jhc.s615781 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Hepatocellular Carcinoma, 2026-08. Verfasst von Yeying Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Yingfu Medical Technology Translation Center, The First Hospital of Lanzhou University, Lanzhou, Gansu, 730030, People's Republic of China. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Objective
Hepatocellular carcinoma (HCC) has poor prognosis and variable immunotherapy response. Resveratrol exhibits anti-HCC activity, but its direct targets and association with immunotherapy response are unclear. This study identifies core resveratrol targets in HCC and evaluates their prognostic and predictive value.
Methods
Resveratrol targets were intersected with TCGA-LIHC differentially expressed genes. A prognostic risk model was built using LASSO-Cox regression. Drug-target binding was assessed by molecular dynamics simulations and qRT-PCR. Single-cell and spatial transcriptomics, cell-cell communication, and a pan-immunotherapy cohort were used to investigate KIF11. An HCC mouse model validated immunomodulatory effects via flow cytometry.
Results
Thirty-four resveratrol-associated targets were identified, enriched in metabolism pathways. A nine-gene risk model showed robust prognostic performance. Resveratrol stably binds to KIF11's ATP-binding pocket. KIF11 is overexpressed in malignant hepatocytes and proliferating T cells; KIF11⁺ cells orchestrate VEGF-mediated microenvironment remodeling. High KIF11 expression correlated with poor prognosis but predicted superior survival in the immunotherapy cohort, a phenomenon attributed to the observation that KIF11-high tumors exhibit both enhanced immunogenicity and active immunosuppression. In vivo, resveratrol enhanced CD8⁺ T cell infiltration, proliferation, effector function, and central memory T cells, while reducing Tregs.
Conclusion
KIF11 drives HCC progression and predicts immunotherapy response. It is a candidate direct resveratrol target and a potential biomarker for patient stratification in immune checkpoint therapy, although further experimental validation is warranted.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Yingfu Medical Technology Translation Center, The First Hospital of Lanzhou University, Lanzhou, Gansu, 730030, People's Republic of China.
- Department of Urology, Lanzhou University Second Hospital, Lanzhou, Gansu, 730030, People's Republic of China.
- Department of General Surgery, The First Hospital of Lanzhou University, Lanzhou, Gansu, 730030, People's Republic of China.
ORCID-Profile: Wenbo Meng
Zitieren
APA
Wang, Y., Wan, S., Qiao, W., Li, R., Zhao, J., & Meng, W. (2026). Multi-Omics and Molecular Simulation Identify KIF11 as a Candidate Direct Target of Resveratrol in Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, Volume 13, 1-26. https://doi.org/10.2147/jhc.s615781
Vancouver
Wang Y, Wan S, Qiao W, Li R, Zhao J, Meng W. Multi-Omics and Molecular Simulation Identify KIF11 as a Candidate Direct Target of Resveratrol in Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma. 2026;Volume 13:1-26. doi:10.2147/jhc.s615781
BibTeX
@article{Wang2026,
author = {Wang, Yeying and Wan, Shun and Qiao, Wanjia and Li, Renpeng and Zhao, Jinyu and Meng, Wenbo},
title = {Multi-Omics and Molecular Simulation Identify KIF11 as a Candidate Direct Target of Resveratrol in Hepatocellular Carcinoma},
journal = {Journal of Hepatocellular Carcinoma},
year = {2026},
volume = {Volume 13},
pages = {1--26},
doi = {10.2147/jhc.s615781}
}
EUVIMED